{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:39:05Z","timestamp":1791070745396,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.phrs.2014.04.012","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T18:00:46Z","timestamp":1400004046000},"page":"107-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Statins and skeletal muscles toxicity: From clinical trials to everyday practice"],"prefix":"10.1016","volume":"88","author":[{"given":"Giuseppe Danilo","family":"Norata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Tibolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico Luigi","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2014.04.012_bib0005","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.phrs.2014.04.012_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0165-6147(97)01147-4","article-title":"Hydrophilicity\/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors","volume":"19","author":"Hamelin","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2014.04.012_bib0015","doi-asserted-by":"crossref","first-page":"28J","DOI":"10.1016\/0002-9149(88)90004-5","article-title":"Efficacy and long-term adverse effect pattern of lovastatin","volume":"62","author":"Tobert","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.04.012_bib0025","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1017\/S0317167100007514","article-title":"A neuromuscular approach to statin-related myotoxicity","volume":"35","author":"Baker","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.phrs.2014.04.012_bib0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.04.012_bib0040","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.phrs.2014.04.012_bib0045","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.phrs.2014.04.012_bib0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"Journal Pathol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0055","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbrc.2005.10.108","article-title":"Simvastatin induces impairment in skeletal muscle while heart is protected","volume":"338","author":"Sirvent","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2014.04.012_bib0060","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/eurheartj\/ehr224","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a \u2018mitohormesis\u2019 mechanism involving reactive oxygen species and PGC-1","volume":"33","author":"Bouitbir","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.phrs.2014.04.012_bib0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.12.121","article-title":"Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins","volume":"12","author":"Morikawa","year":"2005","journal-title":"J Ather Thromb"},{"key":"10.1016\/j.phrs.2014.04.012_bib0070","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","article-title":"Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity","volume":"33","author":"Westwood","year":"2005","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0075","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1039\/c0an00543f","article-title":"Characterization of microRNA-125b expression in MCF7 breast cancer cells by ATR-FTIR spectroscopy","volume":"135","author":"Ozek","year":"2010","journal-title":"Analyst"},{"key":"10.1016\/j.phrs.2014.04.012_bib0080","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbagen.2013.09.010","article-title":"Structural and functional characterization of simvastatin-induced myotoxicity in different skeletal muscles","volume":"1840","author":"Simsek Ozek","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phrs.2014.04.012_bib0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2008.05.021","article-title":"Molecular basis of statin-associated myopathy","volume":"202","author":"Vaklavas","year":"2009","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.phrs.2014.04.012_bib0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/taap.1997.8131","article-title":"Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0095","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bcp.2003.08.011","article-title":"Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors in human myocytes","volume":"66","author":"Nishimoto","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0100","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/CIRCULATIONAHA.110.975284","article-title":"Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia","volume":"123","author":"Stein","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.04.012_bib0105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001648-200109000-00017","article-title":"Lipid-lowering drugs and risk of myopathy: a population-based follow-up study","volume":"12","author":"Gaist","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.phrs.2014.04.012_bib0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0828-282X(06)70253-7","article-title":"Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor","volume":"22","author":"Simard","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2007.03.016","article-title":"Mevalonate pathway: a review of clinical and therapeutical implications","volume":"40","author":"Buhaescu","year":"2007","journal-title":"Clin Biochem"},{"key":"10.1016\/j.phrs.2014.04.012_bib0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.phrs.2014.04.012_bib0125","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1211\/jpp.57.11.0014","article-title":"Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein","volume":"57","author":"Matzno","year":"2005","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0130","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1096\/fj.07-8713com","article-title":"RAB-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers","volume":"21","author":"Sakamoto","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.phrs.2014.04.012_bib0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5551\/jat.E551","article-title":"Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain","volume":"16","author":"Yu","year":"2009","journal-title":"J Ather Thromb"},{"key":"10.1016\/j.phrs.2014.04.012_bib0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2353\/ajpath.2010.091140","article-title":"Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle","volume":"177","author":"Draeger","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0145","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin D deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2014.04.012_bib0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2265.2008.03448.x","article-title":"Vitamin D insufficiency \u2013 a novel mechanism of statin-induced myalgia","volume":"71","author":"Lee","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25(OH) vitamin D levels (<32ng\/ml) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Translat Res"},{"key":"10.1016\/j.phrs.2014.04.012_bib0165","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.1957.72980250010016","article-title":"Drug reactions enzymes, and biochemical genetics","volume":"165","author":"Motulsky","year":"1957","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.phrs.2014.04.012_bib0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/978-3-642-94744-5_2","article-title":"Moderne problem der humangenetik","volume":"12","author":"Vogel","year":"1959","journal-title":"Ergeb Med Kinderheilk"},{"key":"10.1016\/j.phrs.2014.04.012_bib0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/eurheartj\/ehr239","article-title":"A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application","volume":"33","author":"Verschuren","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.phrs.2014.04.012_bib0180","doi-asserted-by":"crossref","first-page":"III50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.04.012_bib0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(10)71063-1","article-title":"Pitavastatin \u2013 pharmacological profile from early phase studies","volume":"11","author":"Catapano","year":"2010","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.phrs.2014.04.012_bib0190","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0195","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/jps.23483","article-title":"Gene\u2013gene\u2013environment interactions between drugs, transporters, receptors, and metabolizing enzymes: statins, SLCO1B1, and CYP3A4 as an example","volume":"102","author":"Sadee","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.phrs.2014.04.012_bib0200","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.phrs.2014.04.012_bib0205","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/FPC.0b013e32834c6edb","article-title":"Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam study","volume":"21","author":"Elens","year":"2011","journal-title":"Pharmacogen Genomics"},{"key":"10.1016\/j.phrs.2014.04.012_bib0210","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy \u2013 a genomewide study","volume":"359","author":"Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.04.012_bib0215","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2014.04.012_bib0220","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.phrs.2014.04.012_bib0225","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/tpj.2010.92","article-title":"Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin","volume":"12","author":"Brunham","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.phrs.2014.04.012_bib0230","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The slco1b1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0235","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.04.012_bib0240","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.04.012_bib0245","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2010.02.026","article-title":"Genetic involvement in statins induced myopathy. Preliminary data from an observational case\u2013control study","volume":"211","author":"Puccetti","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2014.04.012_bib0250","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature12508","article-title":"A statin-dependent QTL for GATM expression is associated with statin-induced myopathy","volume":"502","author":"Mangravite","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2014.04.012_bib0255","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHBLI clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.04.012_bib0260","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the national lipid association statin safety assessment task force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0265","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11883-007-0050-3","article-title":"Statin myopathy: incidence, risk factors, and pathophysiology","volume":"9","author":"Sewright","year":"2007","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.phrs.2014.04.012_bib0270","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1592\/phco.22.17.1524.34130","article-title":"Etiology and frequency of rhabdomyolysis","volume":"22","author":"Black","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2014.04.012_bib0275","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.phrs.2014.04.012_bib0280","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1253\/circj.67.287","article-title":"Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients","volume":"67","author":"Matsuzawa","year":"2003","journal-title":"Circ J"},{"key":"10.1016\/j.phrs.2014.04.012_bib0285","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/jama.1990.03440160047035","article-title":"Prescribed use of cholesterol-lowering drugs in the United States, 1978 through 1988","volume":"263","author":"Wysowski","year":"1990","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.phrs.2014.04.012_bib0290","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.977","article-title":"Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy","volume":"13","author":"Chang","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.phrs.2014.04.012_bib0295","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.04.012_bib0300","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Treating to new targets I. Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.04.012_bib0305","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.04.012_bib0310","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.04.012_bib0315","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.phrs.2014.04.012_bib0320","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","article-title":"Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials","volume":"104","author":"Mills","year":"2011","journal-title":"QJM"},{"key":"10.1016\/j.phrs.2014.04.012_bib0325","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the primo study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.phrs.2014.04.012_bib0330","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","article-title":"Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients","volume":"29","author":"Nichols","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.phrs.2014.04.012_bib0335","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.pharmtox.38.1.389","article-title":"In vitro and in vivo drug interactions involving human CYP3a","volume":"38","author":"Thummel","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0340","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.phrs.2014.04.012_bib0345","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/HJH.0b013e32832e1bd9","article-title":"The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial","volume":"27","author":"Mori","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.phrs.2014.04.012_bib0350","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2014.04.012_bib0355","first-page":"98","article-title":"The effect of coenzyme Q10 in statin myopathy","volume":"33","author":"Zlatohlavek","year":"2012","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.phrs.2014.04.012_bib0360","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0365","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MOL.0b013e3283168ecd","article-title":"Effects of ubiquinone (coenzyme Q10) on myopathy in statin users","volume":"19","author":"Schaars","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.phrs.2014.04.012_bib0370","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/eurheartj\/eht088","article-title":"New therapeutic principles in dyslipidaemia: focus on LDL and LP(A) lowering drugs","volume":"34","author":"Norata","year":"2013","journal-title":"Eur Heart J"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T08:20:50Z","timestamp":1565425250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661814000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":74,"alternative-id":["S1043661814000528"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2014.04.012","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins and skeletal muscles toxicity: From clinical trials to everyday practice","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2014.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}